Brief report: A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma

13Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

This study represents the first report of gene therapy for anaplastic thyroid carcinoma, one of the most aggressive solid tumors in humans. Two patients with end-stage anaplastic thyroid carcinoma were treated by direct intratumor injection of retroviral vector producer cells followed by ganciclovir. The retroviral vector carried the human IL-2 gene and the suicide gene thymidine kinase of herpes simplex virus type 1. Treatment was safe and associated with only mild adverse events. Transduction of tumor cells and production of T helper type 1 cytokines was demonstrated in tumor biopsies. Gene therapy led also to a marked increase in T helper type 1 cytokine expression in peripheral blood mononuclear cells. Radiological evaluation of injected tumor masses demonstrated local tumor necrosis. Copyright © 2005 by The Endocrine Society.

Cite

CITATION STYLE

APA

Barzon, L., Pacenti, M., Taccaliti, A., Franchin, E., Bruglia, M., Boscaro, M., & Palù, G. (2005). Brief report: A pilot study of combined suicide/cytokine gene therapy in two patients with end-stage anaplastic thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 90(5), 2831–2834. https://doi.org/10.1210/jc.2004-2139

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free